Evaluate the immunogenicity and safety of GSK [GlaxoSmithKline] Biological's HPV [human papillomavirus]-16/18 L1/AS04 vaccine [human papillomavirus vaccine MEDI-517] administered intramuscularly according to a 0,1,6 mth [month] schedule in healthy female subjects aged 10-14 yrs [years].

Trial Profile

Evaluate the immunogenicity and safety of GSK [GlaxoSmithKline] Biological's HPV [human papillomavirus]-16/18 L1/AS04 vaccine [human papillomavirus vaccine MEDI-517] administered intramuscularly according to a 0,1,6 mth [month] schedule in healthy female subjects aged 10-14 yrs [years].

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top